Fig. 4.

Global marker expression in human GB plasma samples. (A) Total MV-like vesicle numbers in the plasma from each patient were determined via nanoparticle tracking analysis (NTA). (B) The amount of TMV was determined by first accounting for host cell MV (using a cocktail of CD31, CD41, CD42β, CD45, and CD235a) then staining remaining vesicles for tumor markers (EGFR, EGFRvIII, EpCAM, and IDH1-R132H). TMV were present and detectable in all GB patients analyzed. (C) The relative contribution of TMV to the total MV-like vesicle pool was variable among GB patients. (D) The heterogeneity of EGFR, EGFRvIII, and EpCAM expression (IDH1-R132H was not detected in any of the EV observed) among the subpopulation of TMV for each patient was assessed.